|
| 36108341 | Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. | Blood | 2023 |
| 36108341 | Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. | Blood | 2023 |
| 38033506 | Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. | EClinicalMedicine | 2023 |
| 37729613 | COVID-19 in patients with classic and variant hairy cell leukemia. | Blood Adv | 2023 |
| 37877800 | Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection. | J Med Virol | 2023 |
| 37059834 | Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. | Nat Med | 2023 |
| 36546416 | Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience. | Haematologica | 2023 |
| 37877800 | Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection. | J Med Virol | 2023 |
| 37729613 | COVID-19 in patients with classic and variant hairy cell leukemia. | Blood Adv | 2023 |
| 38033506 | Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. | EClinicalMedicine | 2023 |
| 37059834 | Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. | Nat Med | 2023 |
| 36546416 | Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience. | Haematologica | 2023 |
| 34535326 | Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. | Blood Rev | 2022 |
| 35835913 | Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. | Nat Genet | 2022 |
| 36070610 | Development of a distributed international patient data registry for hairy cell leukemia. | Leuk Lymphoma | 2022 |
| 35851312 | T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. | J Immunother Cancer | 2022 |
| 36509740 | Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. | Blood Cancer J | 2022 |
| 34535326 | Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. | Blood Rev | 2022 |
| 35835913 | Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. | Nat Genet | 2022 |
| 35851312 | T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. | J Immunother Cancer | 2022 |
| 36509740 | Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. | Blood Cancer J | 2022 |
| 36070610 | Development of a distributed international patient data registry for hairy cell leukemia. | Leuk Lymphoma | 2022 |
| 33947938 | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. | Leukemia | 2021 |
| 33754642 | Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. | Blood | 2021 |
| 33627164 | Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. | J Hematol Oncol | 2021 |
| 33947938 | Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. | Leukemia | 2021 |
| 34202156 | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. | J Clin Med | 2021 |
| 34030585 | Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. | Leuk Lymphoma | 2021 |
| 34607348 | Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. | Blood Adv | 2021 |
| 34827694 | Immunotoxins: From Design to Clinical Application. | Biomolecules | 2021 |
| 33627164 | Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. | J Hematol Oncol | 2021 |
| 33754642 | Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. | Blood | 2021 |
| 34607348 | Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. | Blood Adv | 2021 |
| 34827694 | Immunotoxins: From Design to Clinical Application. | Biomolecules | 2021 |
| 34202156 | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. | J Clin Med | 2021 |
| 34030585 | Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. | Leuk Lymphoma | 2021 |
| 31628266 | Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. | Oncologist | 2020 |
| 32077130 | Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. | Br J Clin Pharmacol | 2020 |
| 31628266 | Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. | Oncologist | 2020 |
| 32109194 | Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. | J Clin Oncol | 2020 |
| 31665200 | Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. | Am J Clin Pathol | 2020 |
| 32040482 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia. | PLoS One | 2020 |
| 32756468 | Development of Recombinant Immunotoxins for Hairy Cell Leukemia. | Biomolecules | 2020 |
| 32755330 | Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. | Leuk Lymphoma | 2020 |
| 32893700 | Treatment of hairy cell leukemia. | Expert Rev Hematol | 2020 |
| 31665200 | Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. | Am J Clin Pathol | 2020 |
| 32077130 | Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. | Br J Clin Pharmacol | 2020 |
| 32040482 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia. | PLoS One | 2020 |
| 32756468 | Development of Recombinant Immunotoxins for Hairy Cell Leukemia. | Biomolecules | 2020 |
| 32755330 | Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. | Leuk Lymphoma | 2020 |